Tel Aviv, Israel

Anton Plotkin

This inventor holds 11 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Bluewind Medical Ltd., Leviticus Cardio Ltd.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anton Plotkin. Retrieved from https://idiyas.com/inventor/anton-plotkin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 90.9

 

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 66(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Anton Plotkin - Innovative Inventor from Tel Aviv

Introduction: Anton Plotkin is a renowned inventor based in Tel Aviv, Israel, known for his groundbreaking contributions to various technological fields.

Latest Patents: Anton Plotkin holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With over two decades of experience in the industry, Anton Plotkin has worked with leading research institutions and multinational companies to develop cutting-edge solutions that have revolutionized the way we approach complex challenges.

Collaborations: Throughout his career, Anton Plotkin has collaborated with top scientists, engineers, and entrepreneurs from around the world, fostering a culture of creativity and excellence in all his projects.

Conclusion: Anton Plotkin's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs, making him a true pioneer in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…